Target ALS funds investigators who collaborate across scientific disciplines and research constituencies to drive medical breakthroughs for the treatment of ALS.
By bringing together the right people, funding, tools, and resources, Target ALS is breaking down barriers that have existed for decades, amplifying and accelerating the ALS drug discovery and development process.
Our funding opportunities are open to investigators working worldwide.
Our Grantmaking Process
Open Funding Opportunities
Proposals due March 19, 2024
Recently Closed Funding Opportunities
Upcoming Funding Opportunities
Each year, the Target ALS team strategically designs funding opportunities to accelerate ALS research. We have scheduled the following grants calls for 2024. More details will become available as we approach the announcement date for each call.
- In Vivo Target Validation 1 (Biospective TDP43 Delta NLS) | March 2024
- We have partnered with the contract research organization Biospective to enable evaluation of novel therapeutics for target engagement and disease-modifying potential in a mammalian model of ALS (TDP-43 Delta NLS). Academic and industry labs are encouraged to apply.
- Biomarker Consortia: Cryptic exon & disease progression biomarker development | March 2024
- Target ALS will fund groups of 3-5 labs whose research will identify novel biomarkers to track ALS disease progression and response to therapeutics, including work focused on cryptic exons. Academic and industry partnerships are encouraged but not required.
- In Vivo Target Validation 2 (AAV C9) | June 2024
- We have partnered with Jackson Laboratories to enable evaluation of novel therapeutics for target engagement and disease-modifying potential in a mammalian model of ALS (C9 G4C2 AAV). Academic and industry labs are encouraged to apply.
Participate in the Target ALS Mission
We encourage you to join our mission by using our core facilities or contacting us to discuss how we can help facilitate your work on ALS. To learn about our current and former grant recipients, visit our Funded Consortia page.